title: Did dose escalated radiotherapy in stage III non-small cell lung cancer improve overall survival?
abstract: Radiotherapy has been applied in the treatment for lung cancer patients for many years, especially those with advanced stage disease who cannot be treated with surgery. However, if these advanced stage patients should be treated with standard dosage therapy (60 Gy) or high dosage therapy (>60 Gy) remains a hot debated point. Literature related to this topic would be reviewed here. We believe standard dosage therapy should be strongly recommended, and high dosage therapy might benefit patients with high risk factors patients.
authors.affiliation: Department of Chest Surgery, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650031, China;; Department of Oncology, Kunming Medical University, Kunming 650031, China.
authors.forename: Wei-Wei
authors.initials: WW
authors.lastname: Wang
authors.affiliation: Department of Oncology, Kunming Medical University, Kunming 650031, China;; Department of Gynecological Oncology, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming 650031, China.
authors.forename: Shao-Jia
authors.initials: SJ
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China;; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Zhi-Rui
authors.initials: ZR
authors.lastname: Zhou
keywords: Non-small cell lung cancer (NSCLC); radiotherapy; review